Mr. Speaker, the second petition, which contains 138 signatures, calls upon the House to allow Canadians who have taken part in clinical trials to continue using a trial drug if it has been deemed to have had a positive impact on their condition, even after their trial time has been completed.
In the House of Commons on April 11th, 2019. See this statement in context.